Immune-checkpoint inhibitor-induced colitis in a patient with lung cancer
Journal of Clinical Surgery and Research · 2021
DOI: 10.31579/2768-2757/015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Surgery and Research, 2021. Verfasst von Wei Liu.
Abstract (Originalsprache)
A 62-year-old man was hospitalized in the emergency room because of severe and persistent abdominal pain with bloody diarrhea (14 stools per day over baseline). He had peritoneal signs, with severe periumbilical tenderness and active bowel sounds. Computed tomography of the abdomen revealed thickened wall of the colon. Laboratory evaluation revealed a hemoglobin level of 11.5 g per deciliter (normal range, 13.5 to 17.5). For the previous 4 weeks, the patient had been taking the immune-checkpoint inhibitor toripalimab (targeting programmed death 1, 240 mg once daily) for small-cell lung cancer. Stool tests for Clostridioides difficile infection and other gastrointestinal pathogens yielded negative results. A colonoscopy revealed numerous erosions/ulcers with marked erythema, absent vascular pattern, and friability (Figure A). Biopsy specimens from the colon confirmed severe inflammatory changes, well differentiated glands, crypt abscess, diffuse inflammatory cell infiltration and plasma cell aggregation
Zitieren
APA
Liu, W. (2021). Immune-checkpoint inhibitor-induced colitis in a patient with lung cancer. Journal of Clinical Surgery and Research. https://doi.org/10.31579/2768-2757/015
Vancouver
Liu W. Immune-checkpoint inhibitor-induced colitis in a patient with lung cancer. Journal of Clinical Surgery and Research. 2021. doi:10.31579/2768-2757/015
BibTeX
@article{Liu2021,
author = {Liu, Wei},
title = {Immune-checkpoint inhibitor-induced colitis in a patient with lung cancer},
journal = {Journal of Clinical Surgery and Research},
year = {2021},
doi = {10.31579/2768-2757/015}
}
EUVIMED